LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
作者： R.S. Herbst , F. de Marinis , G. Giaccone , N. Reinmuth , A. Vergnenegre
关键词: Clinical efficacy 、 Visual accommodation 、 Immunohistochemistry 、 Atezolizumab 、 Medicine 、 Oncology 、 PD-L1 、 Chemotherapy regimen 、 Biomarker (medicine) 、 Response Evaluation Criteria in Solid Tumors 、 Internal medicine
摘要: Abstract Background The phase III IMpower110 study (NCT02409342) is evaluating atezo (anti–PD-L1) monotherapy as 1L treatment (tx) in PD-L1–selected patients (pts) with NSCLC independent of tumour histology. IMpower110 met its primary endpoint with significant OS improvement in PD-L1–high (TC3 or IC3;≥ 50% tumour cell [TC] or≥ 10% tumour-infiltrating immune cell [IC]; VENTANA SP142 IHC assay) wild-type (WT; EGFR/ALK-negative) pts (HR, 0.59 [95% CI: 0.40, 0.89]; P= 0.0106). Efficacy analyses in prespecified …
annalsofoncology.org
oup.com
sci-hub.se 参考文章(0)